There is one clinical trial.

Clinical Trials

1 SARS-CoV-2 Specific Memory B and T- CD4+ Cells

The current pandemic caused by the newly identified coronavirus responsible for COVID-19 is a major threat to our populations and societies. Hypothesis/Objective The acquisition of protective immunity at the level of the individual, either through vaccination or natural resolution of the infection, progressively leads at the level of the population to the reduction of the fraction of the population that can be productively infected and transmit the virus, hence, leading to the diminution of the rate of transmission, a phenomenon called herd immunity. Herd immunity was proposed as a strategy to control the infection. However, it remains difficult to model group immunity given the limited knowledge of the interaction between the host immune system with the virus, whose capacity to evolve in face of a neutralizing response is also not known. It is therefore important to acquire a better knowledge of the immunological memory that ensures the resolution of COVID-19 after SARS-CoV2 infection. Method To study single-cell B and T memory cells specific for the anti-SARS-CoV-2 response and characterize somatic mutations of immunoglobulin genes and TCR, in hospitalized and symptomatic patients and in patients cured of SARS-CoV-2.

NCT04402892 COVID-19 SARS-CoV-2 Infection Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)

No related HPO nodes (Using clinical trials)